![portrait of person with blue eyes and blond hair looking in the distance](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2023/07/light-beams-face-theranostic-agents-1296x728-header-1024x575.jpg?w=1155&h=1528)
- Researchers have identified a new radioactive substance called CB-2PA-NT as a promising candidate for a theranostics strategy, combining therapy and diagnostics.
- The substance, which targets neurotensin receptors found in various cancers, demonstrates high uptake and retention in tumors while maintaining a clear distinction from surrounding tissues.
- With regulatory approval pending, researchers hope to conduct human imaging studies using CB-2PA-NT in the near future, which could impact personalized medicine for cancer patients.